New hope for advanced breast cancer? Triple-Drug combo tested after key therapy fails
NCT ID NCT07333937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrink tumors and control the disease longer. Researchers hope to find a new treatment path for patients who have run out of effective options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neratinib combined with fulvestrant and eribulin
What this could lead to
If this works, it could offer a new treatment option for people with a specific type of advanced breast cancer that has stopped responding to a current therapy.
What could go wrong
This is a small, early-phase study (35 people) with no control group, so results may not apply broadly. The drug combination may cause side effects and might not shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••